Novartis International AG http://www.novartis.com Novartis gains European Commission approval for Rasitrio®, a Rasilez-based triple combination pill to treat high blood pressure 2011-11-28T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1566911.shtml Novartis achieves strong third quarter financial performance and pipeline progress 2011-10-25T08:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1557500.shtml Novartis gains positive CHMP opinion for Rasitrio®, first Rasilez-based triple combination pill in Europe to treat high blood pressure 2011-09-23T13:26:29 CET http://www.novartis.com/newsroom/media-releases/en/2011/1549207.shtml Novartis delivers strong financial results and four major approvals in second quarter of 2011 2011-07-19T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1531819.shtml Novartis receives FDA approval for Arcapta(TM) Neohaler(TM), a novel once-daily bronchodilator for chronic obstructive pulmonary disease 2011-07-01T22:38:08 CET http://www.novartis.com/newsroom/media-releases/en/2011/1528013.shtml Novartis receives EU approval for Rasilamlo®, a single-pill combination of aliskiren and amlodipine to treat high blood pressure 2011-04-28T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1509853.shtml Novartis makes strong start for the year 2011-04-19T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1507510.shtml FDA advisory committee recommends US approval of Novartis once-daily bronchodilator QAB149 for COPD 2011-03-09T01:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1495541.shtml Novartis gains positive CHMP opinion for Rasilamlo(TM), a single-pill combination of aliskiren and amlodipine to treat high blood pressure 2011-02-18T14:04:06 CET http://www.novartis.com/newsroom/media-releases/en/2011/1490537.shtml Innovation drives Novartis to double-digit growth for 2010 2011-01-27T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1482782.shtml Novartis delivers excellent performance in third quarter: recently launched products generate 20%* of sales; Gilenya approved; Alcon consolidated 2010-10-21T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1453762.shtml Novartis drug SOM230 is first medical therapy to show efficacy in a Phase III trial in Cushing's disease, a debilitating hormonal disorder 2010-09-22T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1445885.shtml Novartis receives FDA approval of Tekamlo(TM), a single-pill combination of aliskiren and amlodipine to treat high blood pressure 2010-08-27T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1440875.shtml Novartis receives approval in China for Rasilez, a first-in-class direct renin inhibitor for high blood pressure, the leading preventable cause of death in China 2010-07-20T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1432666.shtml Novartis delivers strong financial performance in second quarter, underpinned by increased momentum in innovation 2010-07-15T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1431809.shtml Novartis receives US FDA approval for Zortress® (everolimus) to prevent organ rejection in adult kidney transplant recipients 2010-04-22T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1406625.shtml Novartis healthcare portfolio generates strong growth in first quarter of 2010, progress on delivering innovation, growth and productivity 2010-04-20T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1405499.shtml Novartis achieves record results in 2009 as momentum from recently launched products drives growth across its entire healthcare portfolio 2010-01-26T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1377026.shtml Three new Novartis medicines approved in Japan for patients with type 2 diabetes, high blood pressure and advanced kidney cancer 2010-01-20T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1375090.shtml